AlcHepNet

@AlcHepNet

AlcHepNet ITAALD Trial | Multi-center clinical study advancing research in severe alcohol-associated hepatitis | Collaborative. Innovative. Patient-focused.

Joined January 2019

67 Following 50 Followers 16 Posts

Latest posts 5

AlcHepNet @AlcHepNet Aug 18

New publication alert!

Check out this new AlcHepNet/ITAALD-related publication on adaptive clinical trial design: pubmed.ncbi.nlm.nih.gov/42530482/

AlcHepNet @AlcHepNet Jun 8

The new ARDaC Portal is live!

Our data commons allows you to explore AlcHepNet & TREAT data, expanded proteomics datasets, and the AI-powered Anagine© Summary Report.

🔗 portal.ardac.org

Need access? ardac@iu.edu

#ARDaC #ClinicalResearch

AlcHepNet @AlcHepNet Apr 30

The ITAALD trial is now enrolling patients with sAH.

This multicenter, randomized study evaluates IL-22 (F-652) vs prednisone + integrated AUD therapy (acamprosate + counseling) to improve liver & alcohol-related outcomes.

Learn more clinicaltrials.gov/study/NCT07060…

AlcHepNet @AlcHepNet Apr 16

New publication out in JHEP Reports from @Bernd_Schnabl and team! 🎉

Peptide YY reduces Candida albicans cytotoxicity in alcohol-associated liver disease—opening new directions for microbiome-targeted therapies. 🔗 jhep-reports.eu/article/S2589-…

www.jhep-reports.eu Peptide YY reduces cytotoxicity of Candida albicans in alcohol-associated liver disease Transitioning from yeast to hyphal morphology enables Candida albicans (C. albicans) to secrete candidalysin, invade the intestinal mucosa and translocate to the blood stream. Patients with alcohol...

AlcHepNet @AlcHepNet Mar 30

ITAALD Study now OPEN for enrollment!

We’re enrolling sAH patients (MELD 20–35). If you have patients who may qualify, we’d love to connect.

Active sites: IU, VCU, UTSW, Cleveland Clinic, Mayo Clinic, University of Louisville.

For more details:
alchepnet.org